

Medicines Formulary New additions and changes

Domnisol (calcifediol monohydrate) 266 micrograms capsule for vitamin D deficiencies— Domnisol is a newly launched product licensed for treatment and prevention of vitamin D deficiency and is taken as a once monthly dose. Domnisol was added to the Formulary with a **Green** traffic light status, usually as a second line option. Optimise Rx messaging is in development to support appropriate use where Domnisol may be considered a first line option in specific cohorts of patients.

Dexcom ONE+ sensor for continuous glucose monitoring—Added, **Green**. The ONE+ device is a second generation upgrade from Dexcom One. It is smaller, more accurate, has a reduced warm up period of 30 minutes, requires no separate transmitter, is compatible with share and follow app for up to 10 people and utilises the same Clarity app for healthcare providers. Dexcom One is expected to be discontinued within the next 12 months, the intention is to bulk switch patients from Dexcom One to Dexcom ONE+ via notification message.

Fluticasone nasal drops for nasal polyps— have been reinstated in the Formularies (**Green**), for use when nasal sprays and other first line Formulary options are not effective. The product was previously discontinued and a new manufacturer is now supplying the drops.

Review of oral triptans for migraine

All triptans have been reviewed to rationalise position on the Formulary. Key changes:-

- All triptans given **Green** Formulary status (some previously **SpA**)
- Restrictions added to dispersible products to those unable to swallow
- Frovatriptan restricted to use for menstrual migraine
- Zolmitriptan 5mg tablet removed from Formulary – more cost-effective to prescribe dispersible 5mg tablet.
- Sumatriptan 3mg injection has been added alongside the 6mg injection, as the lower strength is equally efficacious with fewer side effects.

Hertfordshire renal shared care guidelines: phosphate binders and cinacalcet

The below Shared Care documents have been ratified for use in partnership with East and North Herts Trust only:

- Sucroferric oxyhydroxide for hyperphosphatemia in adult patients with end stage renal failure requiring renal replacement therapy
- Cinacalcet for Use in Secondary Hyperparathyroidism in Adults with End Stage Kidney Disease (ESKD) Requiring Renal Replacement Therapy

In addition, the following two SCGs have been updated and are also for use in partnership with East and North Herts Trust only:

- Sevelamer for hyperphosphataemia in adult patients with chronic kidney disease
- Lanthanum for hyperphosphataemia in adult patients with chronic kidney disease

Nutricia Human Breast Milk Fortifier for supplementation of pre-term infants (Milton Keynes only) - Status changed on Formulary from **Red** to **SpIS**—dieticians to advise by way of template letter on continuation of supply, dosage and all other clinical particulars following patient discharge from Milton Keynes hospital. NB: Human Breast Milk Fortifier is a short term course and should therefore only be issued as an acute prescription. The product remains **Red**, hospital only at Bedfordshire and Luton hospitals.

Hydrocortisone 10mg/5mL and 5mg/5mL licensed and unlicensed oral suspensions and solutions —All liquid hydrocortisone has been removed from the Formulary as a range of alternative suitable products have been defined for use in adults and children. See Formulary for full details.

Praziquantel/albendazole for tapeworms—Both products added to Formulary (**Red**). Albendazole is considered the first line choice as it is more readily available and cost-effective vs praziquantel.

Dapagliflozin – removal of lineage on Formulary for Type 2 diabetes (T2DM) - All Formulary SGLT2 inhibitors are now considered equal when considering choice of therapy. The BLMK primary care prescribing guidance in Heart Failure and Chronic Kidney Disease recommends dapagliflozin or empagliflozin and acquisition cost is same for both.

Nystaform HC—Has been added to Milton Keynes Formulary to align with Bedford/Luton Formulary following discontinuation of Daktacort products. Nystaform HC is considered a suitable alternative to Daktacort.

Sativex (cannabis extract) - wording updated to clarify that specialists within community settings may continue prescribing for patients following consultant initiation and stabilisation.